Peptide therapy clinics need medical director oversight built around compounded peptide protocols, not a generic aesthetic standing order, with the goal of keeping every BPC-157, sermorelin, or NAD+ patient chart defensible in front of a state board. Peptides sit closer to the compounding-pharmacy and off-label prescribing gray zone than Botox or filler, so oversight has to cover sourcing, dosing standing orders, and re-check intervals, not just a signature on the wall.
- Medical director for peptide therapy clinics means a physician who signs category-specific standing orders, not a generic aesthetic template.
- BPC-157, TB-500, and other compounded peptides are often sold for indications the FDA hasn’t cleared, which raises the documentation bar.
- US Medical Directors covers standing orders, chart review, and good faith exams under one collaborating physician relationship across many states.
- Refills past 90 days without a re-check exam are the single most common gap in 2026 peptide clinic audits.
- Bulk collaborating physician coverage cuts the cost of scaling peptide programs to a second or third location.
Why medical director oversight matters for peptide therapy clinics
Peptide clinics operate in a different regulatory lane than a standard medspa selling neuromodulators. Many of the peptides driving 2026 demand — BPC-157 for recovery, sermorelin and tesamorelin for growth hormone support, NAD+ for cellular energy — are dispensed through 503A or 503B compounding pharmacies rather than as FDA-approved, ready-made drugs. That means the prescribing physician's sign-off carries more weight than it does for an approved product with a manufacturer insert.
Corporate practice of medicine rules in most states already require a physician owner or medical director for any clinic where a nurse or NP is prescribing. Peptide clinics add a second layer: the standing order has to match the specific compounding pharmacy's formulation, and the chart has to show a documented rationale when a peptide is used off-label. A medical director for peptide therapy clinics closes both gaps at once instead of leaving the clinic to patch them separately.
Map your state's peptide prescribing rules
Start here before signing anything. State rules on compounded peptides move faster than most clinic owners track.
- Check whether your state classifies compounded peptides as prescription-only versus research-use-only
- Confirm whether corporate practice of medicine law requires a physician owner or medical director sign-off for NP/RN-run visits
- Verify your compounding pharmacy is licensed for the specific peptides you dispense, not just licensed in general
- Review the FDA's current bulk drug substances list for what's allowed under 503A/503B compounding in 2026
- Confirm whether NPs or PAs in your state can prescribe peptides independently or need physician collaboration
Audit your current prescribing protocols
Pull the last quarter of peptide orders before you build anything new. Most gaps show up here first.
- Pull the last 90 days of peptide orders and check for a signed standing order behind each one
- Flag any patient started on a peptide without a documented intake exam
- Check dosing ranges against the compounding pharmacy's formulation sheet, not a generic protocol
- Confirm refills aren't auto-approved without a re-check interval
- Note any peptide sold for an indication the FDA hasn't cleared, and check whether the chart documents the off-label rationale
Build standing orders for each peptide category
One blanket peptide standing order doesn't hold up. Split it by category and get physician sign-off on the set, not just individual charts.
- Separate standing orders by category: metabolic/weight peptides, recovery peptides, sexual health peptides, longevity peptides like NAD+
- Set dosing ranges, contraindications, and screening labs required before starting
- Require a re-assessment interval before any refill past 90 days
- Get physician sign-off on the standing order template itself, not only the patient's individual chart
Bring in medical director oversight for sign-off and chart review
This is where a contracted collaborating physician replaces the local-doctor scramble most peptide clinics start with.
- A contracted medical director reviews and signs peptide-specific standing orders instead of a repurposed aesthetic template
- Chart review catches missing labs, expired good faith exams, and off-protocol dosing before a board audit does
- US Medical Directors' collaborating physicians work across many states, which matters if your peptide program runs in more than one location
- This step replaces the scramble to find a local physician willing to sign off — a gap that leaves clinics unable to prescribe for weeks
Get peptide clinic oversight in place
One collaborating physician relationship covering standing orders, chart review, and good faith exams.
Document good faith exams for every new peptide patient
A generic aesthetic exam checklist doesn't cover a peptide intake. Build the exam around the category you're prescribing.
- Confirm the exam covers the specific peptide category (metabolic, recovery, longevity) rather than a generic aesthetic checklist — see how clinics handle this for good faith exams for testosterone therapy clinics
- Store exam records with the standing order they authorize instead of a separate folder
- Set a recurring exam interval matched to your state's requirement, not an arbitrary annual date
- Track exam completion against your active patient roster monthly, not only when a renewal is overdue
Plan for multi-state and telehealth coverage
Many peptide clinics now run consults by telehealth. That adds a state-line problem most owners don't see coming.
- If you prescribe peptides via telehealth, confirm collaborating physician rules in the patient's state, not just the clinic's state
- Line up backup coverage so one collaborating physician's absence doesn't halt prescribing clinic-wide
- Bulk collaborating physician plans reduce per-location cost as you scale to a second or third site
- Confirm the compounding pharmacy you use is licensed to ship into every state you serve
Comparison: oversight options for peptide therapy clinics
| Option | Best for | Key limitation |
|---|---|---|
| In-house employed physician | High-volume clinics needing daily on-site availability | Highest fixed overhead; hard to find a physician who specializes in peptide protocols |
| Local physician handshake agreement | Solo clinics in one state with an existing referral relationship | No backup coverage if that physician leaves, retires, or gets busy |
| Contracted collaborating physician network | Peptide clinics in one or more states that need standing orders, chart review, and good faith exams handled together | Onboarding takes time to align standing orders with each state's rules |
| Telehealth-only medical director platforms | Clinics running peptide consults entirely online | Coverage can lag behind state-specific compounding pharmacy rules |
A contracted collaborating physician network is the best fit for most peptide clinics scaling past a single state in 2026 — it consolidates standing orders, chart review, and good faith exams under one relationship instead of three separate vendors.
Common mistakes peptide therapy clinics make
- Using a generic aesthetic standing order for peptides instead of category-specific dosing and screening criteria
- Selling BPC-157 or other unapproved-for-injury peptides without documenting the off-label rationale in the chart
- Sourcing peptides from a compounding pharmacy without checking it against the current FDA bulk substances list
- Letting refills auto-renew past 90 days without a re-check exam
- Running telehealth peptide consults into a state where the collaborating physician isn't licensed to practice
A clinic that budgets for oversight as a line item, not an afterthought, avoids most of this — see how to budget for medical director costs as a growing medspa for the cost side of this decision.
FAQ
What does a medical director do for a peptide therapy clinic?
A medical director for a peptide therapy clinic signs and reviews standing orders for each peptide category, oversees chart documentation, and confirms prescribing stays inside state and corporate practice of medicine rules. In 2026, that includes reviewing off-label rationale for peptides like BPC-157 that lack FDA approval for the indications they’re sold for.
Is BPC-157 legal to prescribe in medspas in 2026?
BPC-157 is typically dispensed through 503A or 503B compounding pharmacies rather than as an FDA-approved drug, and its legal status depends on your state’s compounding and prescribing rules. A medical director should confirm your compounding pharmacy’s current licensing before you add it to a standing order.
How much oversight does a peptide clinic need if NPs run visits?
Most states require a physician medical director or collaborating physician whenever an NP or RN prescribes peptides under a standing order. The oversight needs to cover the standing order itself, not just a general supervision agreement.
Can one collaborating physician cover peptide clinics in multiple states?
Collaborating physician coverage is state-specific, so a single physician needs licensure in each state where patients are prescribed to. A network model, where different physicians cover different states under one contract, solves this without hiring separately in each market.
What’s the difference between a medical director and a collaborating physician for peptide clinics?
A medical director sets and signs off on clinical protocols and standing orders across the practice, while a collaborating physician is the specific physician paired with an NP or PA under state supervision rules. Many peptide clinics need both roles filled, sometimes by the same physician.
How often do good faith exams need to happen for peptide patients?
The interval is set by state requirement, not by clinic preference, and needs to match the peptide category being prescribed. A recovery peptide patient and a longevity peptide patient don’t need the same exam checklist.
Do I need standing orders for every peptide I sell?
Yes — each peptide category (metabolic, recovery, sexual health, longevity) needs its own standing order with dosing ranges, contraindications, and required screening. A single blanket peptide order doesn’t hold up under chart review.
What happens if my compounding pharmacy loses FDA compliance?
Every standing order tied to that pharmacy’s formulation becomes unenforceable until you switch sources, and any patient mid-treatment needs a documented transition plan. Medical director chart review should flag pharmacy licensing status before it becomes a board finding.
One last thing
The fastest way a peptide clinic ends up in front of a state board in 2026 isn't the peptide itself — it's a refill that auto-renewed past 90 days with no re-check exam behind it. Set that interval as a hard stop in your chart review workflow before you scale to a second location, not after.
Related guides
- Medical director for hormone therapy clinics
- Medical director for testosterone and TRT clinics
- Medical director for NAD IV therapy clinics
